[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.187.2. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Other Articles
September 9, 1950

CLINICAL STUDY OF PREVENTION OF ERYTHROBLASTOSIS WITH Rh HAPTEN

Author Affiliations

Chicago

From the Michael Reese Research Foundation.

JAMA. 1950;144(2):88-92. doi:10.1001/jama.1950.02920020008003
Abstract

Several investigators1 have attempted the extraction of the essential Rh fraction which is undoubtedly present in human Rh-positive erythrocytes. More recently, Carter2 prepared an extract, called it Rh hapten and claimed the following characteristics for such material: (a) inability to generate specific anti-Rh antibodies when injected in vivo by itself; (b) specific neutralization of anti-Rh antibodies in vitro; (c) specific neutralization of anti-Rh antibodies in vivo, i. e., desensitization; (d) clinical value in preventing development of erythroblastosis in pregnant women, and (e) clinical value in treatment of erythroblastotic children. Any substance with the aforementioned characteristics may be called a hapten in accordance with Landsteiner's definition3 for substances incapable of generating specific antibodies in vivo but capable of neutralizing specific antibodies in vitro. A potent Rh hapten might have value clinically if it could "desensitize" pregnant sensitized women who would otherwise have erythroblastotic babies and thus permit the

First Page Preview View Large
First page PDF preview
First page PDF preview
×